Showing results (61-70 of 139) with videos related to
Sort By:
Pageof 14
Haematologica|August 5, 2021
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study GroupGabriele Escherich, Udo Zur Stadt, Arndt Borkhardt, et al.Nature Communications|June 27, 2025
Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemiaJulia Costea, Kerstin K Rauwolf, Pietro Zafferani, et al.Scientific Reports|March 16, 2019
Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemiaElisabeth M P Steeghs, Judith M Boer, Alex Q Hoogkamer, et al.International Journal of Dermatology|July 21, 2021
Mucha-Habermann disease: a pediatric case report and proposal of a risk scoreMartin Ernst Blohm, Chinedu Ulrich Ebenebe, Cornelius Rau, et al.Haematologica|February 19, 2011
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)Gabriele Escherich, Anja Tröger, Ulrich Göbel, et al.Haematologica|June 12, 2013
Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemiaInge van der Sluis, Anja Möricke, Gabriele Escherich, et al.Scientific Reports|January 14, 2018
High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemiaElisabeth M P Steeghs, Marjolein Bakker, Alex Q Hoogkamer, et al.Leukemia|June 6, 2024
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk groupCornelia Eckert, Günter Henze, Karlheinz Seeger, et al.Journal of Adolescent and Young Adult Oncology|December 17, 2016
Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AjET" Working Group of the German Society for Pediatric Oncology and HematologyGabriele Escherich, Stefan Bielack, Stephan Maier, et al.Pageof 14